Article

March 11, 2015

NICE Recommends Gazyvaro for Treatment-Naive CLL Patients

The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.

Patients in England and Wales with chronic lymphocytic leukaemia are a step closer to getting access to Roche’s Gazyvaro (obinutuzumab) on the National Health Service, after cost regulators recommended the drug for routine use.

Gazyvaro is the first ‘type II’ anti-CD20 monoclonal antibody licensed for the treatment of CLL and is designed to attack blood cancers more aggressively than ‘type I’ treatments such as MabThera (rituximab).

Link to the complete article on PharmaTimes: http://bit.ly/1AfH0NA

Related Videos

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Rohan Garje, MD

Susan Escudier, MD, FACP

Sabarish Ayyappan, MD

Susan Escudier, MD, FACP

Screenshot of an interview with Evangelia Vlachou, MD

Screenshot of an interview with Barry Goy, MD

Debra Patt, MD, PhD, MBA, MPH

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions